Franklin Resources Inc. Reduces Stake in Elevance Health, Inc. $ELV

Posted by on Jun 10th, 2026

Franklin Resources Inc. lowered its position in Elevance Health, Inc. (NYSE:ELV – Free Report) by 21.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 838,758 shares of the company’s stock after selling 227,177 shares during the period. Franklin Resources Inc. owned approximately 0.38% of Elevance Health worth $294,027,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Rossby Financial LCC boosted its position in Elevance Health by 110.0% in the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after buying an additional 44 shares during the last quarter. ORG Partners LLC boosted its position in Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after purchasing an additional 59 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in Elevance Health in the 4th quarter worth approximately $38,000. Dorato Capital Management purchased a new stake in Elevance Health in the 4th quarter worth approximately $41,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in Elevance Health in the 4th quarter worth approximately $44,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Up 1.4%

Shares of ELV stock opened at $424.16 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company has a market cap of $92.11 billion, a price-to-earnings ratio of 18.04, a PEG ratio of 2.36 and a beta of 0.67. The stock has a 50 day simple moving average of $360.00 and a 200-day simple moving average of $343.26. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $426.66.

Elevance Health (NYSE:ELV – Get Free Report) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the company posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts expect that Elevance Health, Inc. will post 26.94 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Citigroup upgraded Elevance Health to a “buy” rating in a research report on Wednesday, April 29th. Robert W. Baird upped their price objective on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. Deutsche Bank Aktiengesellschaft upgraded Elevance Health from a “hold” rating to a “buy” rating and upped their price objective for the stock from $363.00 to $498.00 in a research report on Wednesday, May 20th. Sanford C. Bernstein upped their price objective on Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research report on Friday, April 24th. Finally, UBS Group upped their price objective on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $416.11.

Get Our Latest Analysis on ELV

Elevance Health Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Read More

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.